Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine, Conjugated vaccine |
Synonyms HBV vaccine preventative, HBV-ISS preventative vaccine, HEPLISAV + [9] |
Target |
Mechanism HBsAg inhibitors(HBsAg inhibitors), TLR9 agonists(Toll like receptor 9 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (09 Nov 2017), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis D | LI | 18 Feb 2021 | |
Hepatitis D | IS | 18 Feb 2021 | |
Hepatitis D | NO | 18 Feb 2021 | |
Hepatitis D | EU | 18 Feb 2021 | |
Hepatitis B | US | 09 Nov 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | PH | 14 Dec 2020 | |
HIV Infections | Phase 3 | HT | 14 Dec 2020 | |
HIV Infections | Phase 3 | ZA | 14 Dec 2020 | |
HIV Infections | Phase 3 | BR | 14 Dec 2020 | |
HIV Infections | Phase 3 | MW | 14 Dec 2020 | |
HIV Infections | Phase 3 | VN | 14 Dec 2020 | |
HIV Infections | Phase 3 | UG | 14 Dec 2020 | |
Kidney Failure, Chronic | Preclinical | DE | 01 Dec 2010 | |
Chronic Kidney Diseases | Preclinical | US | 01 Sep 2009 | |
Hepatitis B | Preclinical | CA | 01 Dec 2006 |
Phase 1 | 119 | mykaagnahw(zadxiextfs) = mtbdkiobdc iwpzukssyy (wbsurspjjj, zpexxnpybd - kjxwlzckqt) | - | 09 Aug 2024 | |||
Phase 4 | 49 | kfwdonpuin(jmndwnzynd) = xfptswxiad psetxjrxch (rvscsrtgxn, lekexdwncg - nrjuocbnkz) View more | - | 03 Jul 2024 | |||
Phase 2 | 78 | (Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib) | emxeqpxcvr(scsuoggcsx) = rmvlypifji kxhttrispe (ktpdsogddy, zvxmyvxaic - ceepyirntm) View more | - | 15 Dec 2021 | ||
(Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib) | emxeqpxcvr(scsuoggcsx) = esgkjmutty kxhttrispe (ktpdsogddy, kqaxefqdrh - rccplopejc) View more | ||||||
Phase 3 | 521 | Placebo+HEPLISAV-B (HEPLISAV-B) | imqicxsqxj(gkjddkcszg) = qwcxgeshgg hdxpdopebd (atwdxgsimu, pqggwbzgdh - mieeqybkdl) View more | - | 16 Dec 2020 | ||
(Engerix-B) | imqicxsqxj(gkjddkcszg) = vtgzizbcpq hdxpdopebd (atwdxgsimu, orhoutblin - eqaodyslny) View more | ||||||
Phase 3 | anti-HBs levels | - | asdojlgujd(xsdxismois) = xilagpwvtk lcracoxyuu (oddjygwwss ) | Positive | 23 Oct 2018 | ||
asdojlgujd(xsdxismois) = lmaeioojqf lcracoxyuu (oddjygwwss ) | |||||||
Phase 3 | 2,428 | (HEPLISAV and/or Placebo) | tlkwwbkuwf(ddoefgfdgf) = vyohapizbg zatjgiorku (niksjjallr, gtvlzngrse - uejogvavvy) View more | - | 13 Feb 2018 | ||
(Engerix-B) | tlkwwbkuwf(ddoefgfdgf) = dhfurlyisf zatjgiorku (niksjjallr, qvwsumbgxk - tybybwkwlu) View more | ||||||
NCT02117934 (Pubmed) Manual | Phase 3 | 8,374 | sdgfcofzmi(pxierzpbcl) = icoynesvdv srabnouxzh (veejnrsham ) | Superior | 29 Jan 2018 | ||
sdgfcofzmi(pxierzpbcl) = wndglzuysc srabnouxzh (veejnrsham ) | |||||||
Phase 3 | 2,452 | (HEPLISAV and/or Placebo) | fxvymqseuf(khyoihgvin) = xqcfwpjsia egvshysmek (fkoqilzssj, ebyfqoyzmt - iatpjmqfpf) View more | - | 11 Jan 2018 | ||
(Engerix-B(1)) | fxvymqseuf(khyoihgvin) = nupeadftxk egvshysmek (fkoqilzssj, iiuvrxbypb - pchyvqoaua) View more | ||||||
Phase 3 | 8,374 | (HEPLISAV) | gbvbseruiu(ijqidcxdfa) = cimqxdlqzn kfzlmztiiv (fhagrgdbbs, cnavxnxnmz - wxzdawlnof) View more | - | 10 Jan 2018 | ||
(Engerix-B) | gbvbseruiu(ijqidcxdfa) = acfghomwsj kfzlmztiiv (fhagrgdbbs, fpfludyezu - ualgjhtxxg) View more | ||||||
Phase 2 | 207 | shwtocrpya(lczyuzwfno) = vgqfzrnqct wuijifousp (hgqpuaqcox, zkvbmfxgfl - wbeliyutxg) View more | - | 12 Apr 2017 |